Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Ebola virus does not block apoptotic signaling pathways.

Olejnik J, Alonso J, Schmidt KM, Yan Z, Wang W, Marzi A, Ebihara H, Yang J, Patterson JL, Ryabchikova E, Mühlberger E.

J Virol. 2013 May;87(10):5384-96. doi: 10.1128/JVI.01461-12. Epub 2013 Mar 6.

2.

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Olejnik J, Forero A, Deflubé LR, Hume AJ, Manhart WA, Nishida A, Marzi A, Katze MG, Ebihara H, Rasmussen AL, Mühlberger E.

J Virol. 2017 May 12;91(11). pii: e00179-17. doi: 10.1128/JVI.00179-17. Print 2017 Jun 1.

3.

Functional CD8+ T cell responses in lethal Ebola virus infection.

Bradfute SB, Warfield KL, Bavari S.

J Immunol. 2008 Mar 15;180(6):4058-66.

4.

Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.

Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF.

J Virol. 2010 Mar;84(6):3004-15. doi: 10.1128/JVI.02459-09. Epub 2010 Jan 13.

5.

Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.

Cárdenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martínez-Sobrido L, Saphire EO, Basler CF.

J Virol. 2006 Jun;80(11):5168-78.

6.

Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.

Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF.

J Virol. 2006 Jun;80(11):5156-67.

7.

Ebolavirus VP35 is a multifunctional virulence factor.

Leung DW, Prins KC, Basler CF, Amarasinghe GK.

Virulence. 2010 Nov-Dec;1(6):526-31. Epub 2010 Nov 1.

8.

Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.

Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB.

Virology. 2002 Feb 1;293(1):15-9.

9.

Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection.

Miller ME, Adhikary S, Kolokoltsov AA, Davey RA.

J Virol. 2012 Jul;86(14):7473-83. doi: 10.1128/JVI.00136-12. Epub 2012 May 9.

10.

Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation.

Yen B, Mulder LC, Martinez O, Basler CF.

J Virol. 2014 Nov;88(21):12500-10. doi: 10.1128/JVI.02163-14. Epub 2014 Aug 20.

11.

Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells.

Harcourt BH, Sanchez A, Offermann MK.

Virology. 1998 Dec 5;252(1):179-88.

12.
13.

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215. Epub 2015 May 4.

PMID:
25943199
14.

Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway.

Fabozzi G, Nabel CS, Dolan MA, Sullivan NJ.

J Virol. 2011 Mar;85(6):2512-23. doi: 10.1128/JVI.01160-10. Epub 2011 Jan 12.

15.

Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.

Zhang X, Ao Z, Bello A, Ran X, Liu S, Wigle J, Kobinger G, Yao X.

Antiviral Res. 2016 Mar;127:20-31. doi: 10.1016/j.antiviral.2016.01.001. Epub 2016 Jan 9.

PMID:
26778707
16.

Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.

Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG.

J Virol. 2015 Oct;89(20):10399-406. doi: 10.1128/JVI.01736-15. Epub 2015 Aug 5.

17.

Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.

Hill-Batorski L, Halfmann P, Marzi A, Lopes TJ, Neumann G, Feldmann H, Kawaoka Y.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S329-35. doi: 10.1093/infdis/jiv335. Epub 2015 Jul 23.

18.

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74. doi: 10.1093/infdis/jir348.

19.

A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire.

Boehmann Y, Enterlein S, Randolf A, Mühlberger E.

Virology. 2005 Feb 5;332(1):406-17.

20.

Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis.

Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, Hotchkiss RS, Bavari S.

J Immunol. 2010 Jan 1;184(1):327-35. doi: 10.4049/jimmunol.0901231.

Supplemental Content

Support Center